# Bert Vogelstein

Source: https://onco.cc/people/bert-vogelstein/  
OnCo record `bert-vogelstein` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bert Vogelstein is the most-cited scientist in cancer genetics: he mapped how colorectal cancer develops and founded the field of cancer genome sequencing and blood-based detection.

## Summary

Bert Vogelstein is Clayton Professor of Oncology, Co-Director of the Ludwig Center and an HHMI Investigator at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is the most-cited scientist in cancer genetics, having mapped with Kenneth Kinzler how colorectal cancer develops through the adenoma-carcinoma sequence, discovered the tumour-suppressor role of p53 and sequenced the first cancer genomes. His selected papers survey cancer genome landscapes and describe detection and localisation of surgically resectable cancers with a multi-analyte blood test. That test, CancerSEEK, is the basis of multi-cancer early detection, and his laboratory continues to work on liquid biopsy and blood-based screening.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Clayton Professor of Oncology; Co-Director, Ludwig Center; HHMI Investigator
- Specialisms: Cancer genetics; Colorectal tumorigenesis; Liquid biopsy; Early detection

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Bert_Vogelstein
- Ludwig Center: https://www.hopkinsmedicine.org/kimmel-cancer-center/research/ludwig-center
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Vogelstein%20B%5BAuthor%5D

## Connected records

- cancers: [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors](https://onco.cc/cancers/ipmn-cystic-precursors/), [Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma](https://onco.cc/cancers/msi-high-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- targets: [KRAS](https://onco.cc/targets/kras/), [TP53](https://onco.cc/targets/tp53/)
- institutions: [Howard Hughes Medical Institute](https://onco.cc/institutions/hhmi/), [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://onco.cc/institutions/johns-hopkins/), [Lustgarten Foundation](https://onco.cc/institutions/lustgarten-foundation/)
- key papers: [A combination of molecular markers and clinical features improve the classification of pancreatic cysts](https://onco.cc/key-papers/paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015/), [A genetic model for colorectal tumorigenesis](https://onco.cc/key-papers/paper-fearon-cell/), [Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful](https://onco.cc/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/), [Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer](https://onco.cc/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/), [Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers](https://onco.cc/key-papers/paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017/), [Core signaling pathways in human pancreatic cancers revealed by global genomic analyses](https://onco.cc/key-papers/paper-jones-pancreatic-core-pathways-science-2008/), [DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms](https://onco.cc/key-papers/paper-detect-a-science-2020/), [Detection and localization of surgically resectable cancers with a multi-analyte blood test](https://onco.cc/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/), [Distant metastasis occurs late during the genetic evolution of pancreatic cancer](https://onco.cc/key-papers/paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010/), [DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer](https://onco.cc/key-papers/paper-dynamic-nejm-2022/), [El-Deiry 1993: WAF1, the gene through which p53 stops cell division](https://onco.cc/key-papers/paper-el-deiry-waf1-p21-cell-1993/), [Genetic alterations during colorectal-tumor development](https://onco.cc/key-papers/paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988/), [Genetic instability in colorectal cancers](https://onco.cc/key-papers/paper-lengauer-genetic-instability-colorectal-nature-1997/), [Hollstein 1991: p53 mutations in human cancers](https://onco.cc/key-papers/paper-hollstein-p53-mutations-science-1991/), [Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability](https://onco.cc/key-papers/paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995/), [Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma](https://onco.cc/key-papers/paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998/), [Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ](https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/), [Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer](https://onco.cc/key-papers/paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017/), [Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia](https://onco.cc/key-papers/paper-kanda-panin-1-somatic-mutations-gastroenterology-2012/), [Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development](https://onco.cc/key-papers/paper-wu-gnas-ipmn-sci-transl-med-2011/), [The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers](https://onco.cc/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/), [Vogelstein, Lane and Levine 2000: surfing the p53 network](https://onco.cc/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/), [Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways](https://onco.cc/key-papers/paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011/)
- terms: [DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms](https://onco.cc/terms/detect-a-study/), [Driver and passenger mutations: the refined somatic mutation theory](https://onco.cc/terms/driver-passenger-model/), [Somatic mutation theory of cancer](https://onco.cc/terms/somatic-mutation-theory/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/)
- pathways: [Theories of cancer: how the ideas connect](https://onco.cc/pathways/theories-of-cancer/)

---
JSON: https://onco.cc/api/v1/entities/bert-vogelstein.json